Shikiar Asset Management Inc. Invests $665,000 in Urogen Pharma (URGN)
Shikiar Asset Management Inc. bought a new stake in Urogen Pharma (NASDAQ:URGN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 21,100 shares of the company’s stock, valued at approximately $665,000. Shikiar Asset Management Inc. owned 0.16% of Urogen Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Alps Advisors Inc. bought a new stake in shares of Urogen Pharma in the second quarter valued at about $195,000. LLBH Private Wealth Management LLC bought a new stake in shares of Urogen Pharma in the second quarter valued at about $695,000. Spark Investment Management LLC bought a new stake in shares of Urogen Pharma in the second quarter valued at about $856,000. Menora Mivtachim Holdings LTD. bought a new stake in shares of Urogen Pharma in the second quarter valued at about $2,331,000. Finally, Wildcat Capital Management LLC bought a new stake in shares of Urogen Pharma in the second quarter valued at about $2,439,000. Institutional investors and hedge funds own 36.06% of the company’s stock.
Several research firms recently weighed in on URGN. Zacks Investment Research upgraded shares of Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, August 2nd. Oppenheimer Holdings, Inc. set a $32.00 target price on shares of Urogen Pharma and gave the company a “buy” rating in a research note on Monday, August 14th. Finally, Jefferies Group LLC increased their target price on shares of Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, October 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $28.50.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/20/shikiar-asset-management-inc-invests-665000-in-urogen-pharma-urgn.html.
Urogen Pharma (NASDAQ URGN) traded down 1.02% during midday trading on Friday, hitting $27.18. 17,883 shares of the company traded hands. The company’s market capitalization is $353.58 million. Urogen Pharma has a 12-month low of $13.01 and a 12-month high of $33.77. The stock’s 50-day moving average price is $29.70 and its 200 day moving average price is $21.36.
About Urogen Pharma
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Urogen Pharma (NASDAQ:URGN).
Receive News & Stock Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related stocks with our FREE daily email newsletter.